effect of soymilk intake on inflammatory markers and oxidative stress

Comparison of the effects of soy milk and cow's milk intake on the levels of inflammatory markers, proinflammatory cytokines and oxidative stress in patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013030312689N1

Enrollment

Registered

2013-08-02

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Seropositive rheumatoid arthritis

Interventions

Intervention 1: intervention group: daily consumption of 200 ml calcium-fortified soy milk (1% fat) for 4 weeks. produced by Soya Sun Company, in Iran. Intervention 2: control group: daily consumption

Treatment - Other

intervention group: daily consumption of 200 ml calcium-fortified soy milk (1% fat) for 4 weeks. produced by Soya Sun Company, in Iran.

control group: daily consumption of 200 ml cow's milk (1.5% fat) for 4 weeks. produced by Mihan-Dairy Company, in Iran.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-65 years old patient who have Rheumatoid Arthritis according to revised American Rheumatism Association criteria and Rheumatologist diagnosis. The type and dose of drug medication remain constant since 1 month prior and during of the study. Exclusion criteria: Patients who have chronic disease such as diabetes, cardiovascular, hepatic, kidney, gastrointestinal diseases, and severe infection. Smoking, alcohol consumption, use of dietary supplements and having allergy to soy products or cow’s milk.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;IL-1. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;IL-6. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Leptin. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;RF. Timepoint: at baseline and end of each intervention. Method of measurement: Nephlometry.;MDA. Timepoint: at baseline and end of each intervention. Method of measurement: Spectrophotometric.	—

Measure

Time frame

TNF-a. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;IL-1. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Hs-CRP. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;IL-6. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Adiponectin. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;Leptin. Timepoint: at baseline and end of each intervention. Method of measurement: ELISA.;RF. Timepoint: at baseline and end of each intervention. Method of measurement: Nephlometry.;MDA. Timepoint: at baseline and end of each intervention. Method of measurement: Spectrophotometric.

—

Secondary

Measure	Time frame
Blood Pressure. Timepoint: at baseline and end of each intervention. Method of measurement: Blood Pressure Monitor.;Weight. Timepoint: at baseline and end of each intervention. Method of measurement: digital scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Choghakhori

School of Paramedicine, Ahvaz Jondishapur University Of Medical Sciences

choghakhori.r@ajums.ac.ir+98 61 1373 8254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026